載入中
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
最新資料
US$11.46
−US$0.31 · -2.63%
盤中時間採用ET。市場資料可能有所延遲。
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
盤中時間採用ET。市場資料可能有所延遲。
BrainsWay Ltd. develops and distributes non-invasive neurostimulation therapies that address a broad spectrum of mental health and neurological conditions. The company operates globally, with a presence in the United States, Europe, and Israel, among other international markets. Its primary offering is the Deep Transcranial Magnetic Stimulation (dTMS) platform technology, which provides treatment for various ailments including major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post-stroke rehabilitation, and Parkinson's disease. BrainsWay's clientele primarily comprises medical professionals, hospitals, and medical centers specializing in psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel.
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 5222.5萬 USD | 4101.6萬 USD | 3178.5萬 USD | 2717.7萬 USD | 2965.7萬 USD |
| 銷貨成本 | 1283.9萬 USD | 1043.5萬 USD | 830.8萬 USD | 712.9萬 USD | 659.9萬 USD |
| 毛利 | 3938.6萬 USD | 3058.1萬 USD | 2347.7萬 USD | 2004.8萬 USD | 2305.8萬 USD |
| 研究與開發 | 960.3萬 USD | 719萬 USD | 666.5萬 USD | 767.8萬 USD | 639.3萬 USD |
| 銷售、一般及管理費用 | 2546萬 USD | 2200萬 USD | 2163.8萬 USD | 2505.3萬 USD | 2166.4萬 USD |
| 營業費用 | 3506.3萬 USD | 2919萬 USD | 2843.6萬 USD | 3273.1萬 USD | 2805.7萬 USD |
| 利息收入 | 564.04萬 USD | 247.7萬 USD | 217.1萬 USD | 110.9萬 USD | 22.5萬 USD |
| 利息支出 | 222.65萬 USD | 135.6萬 USD | 29.8萬 USD | 6.8萬 USD | 14.1萬 USD |
| 折舊和攤銷 | 153.8萬 USD | 177.1萬 USD | 133.7萬 USD | 153.4萬 USD | 168.6萬 USD |
| 營業利益 | 432.3萬 USD | 139.1萬 USD | −495.9萬 USD | −1268.3萬 USD | −499.9萬 USD |
| 淨利 | 763.3萬 USD | 292.1萬 USD | −419.7萬 USD | −1334.9萬 USD | −646.2萬 USD |
公司資料更新於 2026年10月13日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
報告持有此股票曝險的交易所交易基金。
ARK Israel Innovative Technology ETFIZRL172.84萬1.31%1.34億 USD0.49%US$27.9458-1.44%
Amplify BlueStar Israel Technology ETFITEQ82.95萬0.78%1.08億 USD0.75%US$60.56-2.41%
ActivePassive International Equity ETFAPIE20.65萬0.02%11.41億 USD0.45%US$38.40-0.41%
Even Herd Long Short ETFEHLS17.64萬0.30%5811萬 USD2.62%US$25.3799-0.35%
iShares Neuroscience and Healthcare ETFIBRN4.21萬0.66%635.78萬 USD0.47%US$31.509-0.77%
Defiance Autism Impact ETFASD2.9萬2.19%132.35萬 USD0.79%US$26.6246+0.04%ARK Israel Innovative Technology ETFIZRLAmplify BlueStar Israel Technology ETFITEQActivePassive International Equity ETFAPIEEven Herd Long Short ETFEHLSiShares Neuroscience and Healthcare ETFIBRNDefiance Autism Impact ETFASDAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
